Literature DB >> 30721455

Direct oral anticoagulant successfully used to treat an adult nephrotic patient complicated with portal vein thrombosis.

Fumiaki Obata1, Hideharu Abe2, Taichi Murakami1, Sayo Ueda1, Taizo Inagaki1, Masanori Minato1, Hiroyuki Ono1, Kenji Nishimura1, Eriko Shibata1, Masanori Tamaki1, Fumi Kishi1, Seiji Kishi1, Kojiro Nagai1, Toshio Doi1.   

Abstract

Thromboembolism is a major complication of nephrotic syndrome, with the renal vein being the most frequent site. However, the incidence of portal vein thrombosis (PVT) in patients with nephrotic syndrome is rare. We report a case of a relapsed steroid-dependent minimal change disease with incidental PVT. A 38-year-old man presented with anasarca. Elevated liver enzymes were discovered during routine blood testing within days after commencing treatment. Although drug-induced liver injuries are frequently observed with mild aminotransferase abnormality during therapy with steroid or immune-suppressive agents, imaging revealed a massive thrombus of the portal vein, which was treated by anticoagulant therapy with edoxaban. Treatment with anticoagulant therapy could normalize liver function. Two months after the initiation of treatment with edoxaban, the follow-up CT scan and ultrasound showed the disappearance of PVT. Our case suggests that much attention should be paid to PVT as a cause of liver enzyme elevation when treating patients with nephrotic syndrome.

Entities:  

Keywords:  Direct oral anticoagulant; Liver enzyme elevation; Nephrotic syndrome; Portal vein thrombosis

Mesh:

Substances:

Year:  2019        PMID: 30721455      PMCID: PMC6450988          DOI: 10.1007/s13730-019-00381-9

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  14 in total

1.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Clive Kearon; Elie A Akl; Anthony J Comerota; Paolo Prandoni; Henri Bounameaux; Samuel Z Goldhaber; Michael E Nelson; Philip S Wells; Michael K Gould; Francesco Dentali; Mark Crowther; Susan R Kahn
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  Portal vein thrombosis, revisited.

Authors:  Massimo Primignani
Journal:  Dig Liver Dis       Date:  2009-09-18       Impact factor: 4.088

Review 3.  Low-molecular-weight heparins.

Authors:  J I Weitz
Journal:  N Engl J Med       Date:  1997-09-04       Impact factor: 91.245

Review 4.  Hypercoagulability in cirrhosis: causes and consequences.

Authors:  A Tripodi; Q M Anstee; K K Sogaard; M Primignani; D C Valla
Journal:  J Thromb Haemost       Date:  2011-09       Impact factor: 5.824

Review 5.  Thrombosis in nephrotic syndrome.

Authors:  Biagio Barbano; Antonietta Gigante; Antonio Amoroso; Rosario Cianci
Journal:  Semin Thromb Hemost       Date:  2013-04-27       Impact factor: 4.180

Review 6.  Nephrotic syndrome with portal, splenic and renal vein thrombosis. A case report.

Authors:  Yuki Etoh; Isao Ohsawa; Takayuki Fujita; Yoshinobu Fuke; Morita Endo; Hiroyuki Ohi; Kazunari Kumasaka
Journal:  Nephron       Date:  2002       Impact factor: 2.847

Review 7.  Kidney disease and venous thromboembolism: Does being woman make the difference?

Authors:  A Gigante; F Di Mario; A Pierucci; A Amoroso; F S Pignataro; L Napoleone; S Basili; V Raparelli
Journal:  Eur J Intern Med       Date:  2017-03-01       Impact factor: 4.487

8.  High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study.

Authors:  Bakhtawar K Mahmoodi; Min Ki ten Kate; Femke Waanders; Nic J G M Veeger; Jan-Leendert P Brouwer; Liffert Vogt; Gerjan Navis; Jan van der Meer
Journal:  Circulation       Date:  2007-12-24       Impact factor: 29.690

Review 9.  Venous thrombosis: a multicausal disease.

Authors:  F R Rosendaal
Journal:  Lancet       Date:  1999-04-03       Impact factor: 79.321

Review 10.  Direct-Acting Oral Anticoagulants as Prophylaxis Against Thromboembolism in the Nephrotic Syndrome.

Authors:  Donal J Sexton; Declan G de Freitas; Mark A Little; Tomas McHugh; Colm Magee; Peter J Conlon; Conall M O'Seaghdha
Journal:  Kidney Int Rep       Date:  2018-03-03
View more
  1 in total

Review 1.  Role of direct oral anticoagulants in patients with kidney disease.

Authors:  Vimal K Derebail; Michelle N Rheault; Bryce A Kerlin
Journal:  Kidney Int       Date:  2019-12-24       Impact factor: 10.612

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.